Ipilimumab use in a named-patient program in metastatic melanoma: Experiences in 185 German patients.
Christoph Eichhorn
No relevant relationships to disclose
Max Schlaak
Honoraria - Bristol-Myers Squibb
Jessica C. Hassel
Consultant or Advisory Role - Bristol-Myers Squibb
Honoraria - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb
Carmen Loquai
Consultant or Advisory Role - Bristol-Myers Squibb; Celgene; Roche
Honoraria - Bristol-Myers Squibb; Roche
Other Remuneration - Bristol-Myers Squibb; LEO Pharma; Merck Sharp & Dohme; Roche
Ingo Stoffels
No relevant relationships to disclose
Ralf Gutzmer
Consultant or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; Merck Sharp & Dohme; Novartis
Honoraria - Amgen; GlaxoSmithKline; Merck Serono; Merck Sharp & Dohme; Roche
Research Funding - Novartis; Roche
Other Remuneration - Bristol-Myers Squibb; Merck Sharp & Dohme; Roche
Sylvie Paetzold
Consultant or Advisory Role - Bristol-Myers Squibb
Honoraria - Bristol-Myers Squibb
Ulrich Keller
Consultant or Advisory Role - Bristol-Myers Squibb
Honoraria - Bristol-Myers Squibb
Jens Ulrich
Consultant or Advisory Role - Bristol-Myers Squibb
Honoraria - Bristol-Myers Squibb
Athanasios Tsianakas
No relevant relationships to disclose
Friederike Egberts
No relevant relationships to disclose
Eva Janssen
No relevant relationships to disclose
Claus Garbe
Consultant or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; LEO Pharma; Merck Sharp & Dohme; Philogen; Roche
Honoraria - Roche
Thomas K. Eigentler
Consultant or Advisory Role - Bristol-Myers Squibb; LEO Pharma; Philogen
Honoraria - Bristol-Myers Squibb; Roche